590
Participants
Start Date
October 31, 2007
Primary Completion Date
August 31, 2009
Study Completion Date
October 31, 2011
Darunavir (DRV)
DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
Ritonavir (rtv)
DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
Phoenix
Little Rock
Beverly Hills
Oakland
Palm Springs
Fort Lauderdale
Fort Laudersale
Miami
Miami Beach
Orlando
Safety Harbor
West Palm Beach
Atlanta
Macon
Savannah
Chicago
Springfield
Berkley
Newark
Albany
New York
Rochester
The Bronx
Huntersville
Winston-Salem
Akron
Charleston
Dallas
Harlingen
Houston
Buenos Aires
Córdoba
Guernica
Neuquén
Rosario
Darlinghurst
Surry Hills
Vienna
Curitiba
Distrito Barao Geraldo-Campina
Pinheiros
Recife
Rio de Janeiro
Salvador
São Paulo
Providencia
Santiago
Lyon
Nice
Orléans
Paris
Vandœuvre-lès-Nancy
Berlin
Cologne
München
Guatemala City
Budapest
Ipoh
Kuala Lumpur
Pulau Pinang
Sungai Buloh
Panama City
San Juan
Bucharest
Constanța
Iași
Timișoara
Cape Town
Cyrildene Johannesburg Gauteng
Dundee
Durban
Houghton, Johannesburg
Johannesburg
Pretoria
Westdene Johannesburg Gauteng
Barcelona
Madrid
Kaohsiung County
Taichung
Taipei
Bangkok
Chiang Mai
Khon Kaen
Nonthaburi
London
Tibotec Pharmaceuticals, Ireland
INDUSTRY